Distinguished Gynecologic Oncology Experts to Guide Olvi-Vec Development Efforts SAN DIEGO, June 4, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, today announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will
Continues Preparation of Registrational Trial of Olvi-Vec in the Treatment of Platinum-Refractory/Resistant Ovarian Cancer Patients SAN DIEGO, May 7, 2020 /PRNewswire/ -- Genelux Corporation, a privately-held, clinical-stage immunotherapy company, today announced the outcome of a Type C meeting
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
